Virginia Rossow
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Virginia Rossow has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Alicia González
Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany
1 shared publicationJasmin Berger
Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany
1 shared publicationJulian Berges
Division of Pediatric Pulmonology and Allergology and Cystic Fibrosis Center, Department of Pediatrics, University of Heidelberg, Heidelberg, Germany
1 shared publication- Marcus Alexander Mall
Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany
1 shared publication - Mirjam Stahl
Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany
1 shared publication - Olaf Sommerburg
Division of Pediatric Pulmonology & Allergy and Cystic Fibrosis Center, Department of Pediatrics, University of Heidelberg, Heidelberg, Germany
1 shared publication
Latest Publications
- Open Access
- 24 September 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- p. 2600422
Elexacaftor/tezacaftor/ivacaftor improves CFTR function to near-normal levels in children with cystic fibrosis
Background: The CFTR modulator therapy elexacaftor/tezacaftor/ivacaftor (ETI) improves CFTR function in adolescents and adults with cystic fibrosis (CF) carrying at least one F508del allele to around 40% of median CFTR activity in non-CF controls. This partial restoration of CFTR function is associated with residual mucus dysfunction, airway infection and inflammation. In clinical trials, ETI led to a larger reduction of sweat chloride concentration in children compared to adolescents and adults with CF. However, the degree of correction of CFTR function by ETI in children with CF is currently unknown. Therefore, the aim of this study was to quantify restoration of CFTR function in children with CF aged 2 to 11 years and one or two F508del alleles. Methods: This prospective observational multicenter study quantified restoration of CFTR function by intestinal current measurements (ICM) before and 4 months after initiation of ETI. Additionally, we performed a combined analysis of the effects of ETI in children and our previous study in adolescents and adults with CF. Results: A total of 26 children with CF and at least one F508del allele were enrolled in this study. ETI improved cAMP-induced chloride secretory response to a median of 89.5% (IQR, 51.4 to 125.3; p2 =0.43 and R 2 =0.53 respectively, both pF508del allele.
- 24 September 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- p. 2600422
Open AccessElexacaftor/tezacaftor/ivacaftor improves CFTR function to near-normal levels in children with cystic fibrosis
Background: The CFTR modulator therapy elexacaftor/tezacaftor/ivacaftor (ETI) improves CFTR function in adolescents and adults with cystic fibrosis (CF) carrying at least one F508del allele to around 40% of median CFTR activity in non-CF controls. This partial restoration of CFTR function is associated with residual mucus dysfunction, airway infection and inflammation. In clinical trials, ETI led to a larger reduction of sweat chloride concentration in children compared to adolescents and adults with CF. However, the degree of correction of CFTR function by ETI in children with CF is currently unknown. Therefore, the aim of this study was to quantify restoration of CFTR function in children with CF aged 2 to 11 years and one or two F508del alleles. Methods: This prospective observational multicenter study quantified restoration of CFTR function by intestinal current measurements (ICM) before and 4 months after initiation of ETI. Additionally, we performed a combined analysis of the effects of ETI in children and our previous study in adolescents and adults with CF. Results: A total of 26 children with CF and at least one F508del allele were enrolled in this study. ETI improved cAMP-induced chloride secretory response to a median of 89.5% (IQR, 51.4 to 125.3; p2 =0.43 and R 2 =0.53 respectively, both pF508del allele.